Contracts › 75A50122C00079
75A50122C00079: The Objective of This Contract Is to Develop a Second-Generation Assay for the Oraquick Ebola Rapid Antigen Test As a Sustainable, Enhanced Test Including Alternative Reagents (Antibody and Antigen) With Continued Availability, Extended Shelf-Life, a
Awarded to Orasure Technologies Inc by Office of Assistant Secretary for Preparedness and Response.
$15.5Mobligated
$15.5Mpotential value
30 June 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75A50122C00079 |
|---|---|
| Awardee | Orasure Technologies Inc |
| Awarding agency | Office of Assistant Secretary for Preparedness and Response |
| Awarding office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN13 Health R&D Services; Health Care Services; Experimental Development |
| Place of performance | PA |
| Offers received | 1 |
| Period of performance | 03 January 2023 to 30 June 2027 |
| Potential end | 30 June 2027 |
| Estimated recompete solicitation | ~Q1 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record